IP Library › Patent Application 16284453
Patent Application
App. No. 16/284,453

Sustained Release Formulation Of Naltrexone

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/284,453
Abstract

A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.

Claims (5)

1 - 42 . (canceled)

43 . An oral dosage form, comprising:

a sustained-release formulation of naltrexone or a pharmaceutically acceptable salt thereof, and

bupropion or a pharmaceutically acceptable salt thereof.

44 . A method of treating overweight or obesity, the method comprising administering the oral dosage form of claim 43 .

Assignments (4)
SECURITY INTEREST Recorded Dec 19, 2019
From: CURRAX PHARMACEUTICALS LLC; NALPROPION PHARMACEUTICALS LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB
Reel/Frame 051377/0958 →
CHANGE OF NAME Recorded Oct 17, 2019
From: NALPROPION PHARMACEUTICALS, INC.
To: NALPROPION PHARMACEUTICALS LLC
Reel/Frame 050750/0497 →
RELEASE OF SECURITY INTEREST Recorded Sep 27, 2019
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: NALPROPION PHARMACEUTICALS, INC.
Reel/Frame 050520/0149 →
SECURITY INTEREST Recorded May 6, 2019
From: NALPROPION PHARMACEUTICALS, INC.
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 049092/0156 →